YOLFTbeta
Circio Holding ASA

Circio Holding ASA

CRNA · OL · Healthcare / Biotechnology

9.36NOK+0.05 (+0.54%)

Price History

Full chart

Market Stats

Previous Close9.31
Open9.36
Day Range9.15 – 9.64
52-Week Range0.612 – 15.70
Volume2.97M
Market Cap3.11B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.37
Dividend Yield0.00%
Beta-1.11
50-Day Avg10.66
200-Day Avg7.03

About

Circio Holding ASA, a biotechnology company, develops novel circular RNA expression technology for gene and cell therapy. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three clinical trials for multiple myeloma, and pancreatic and lung cancer; and circVec circRNA vector platform, a modular genetic cassette for biogenesis of multifunctional circRNAs in human cells. It has a research collaboration with United Immunity Co., Ltd. for the development of vivo CAR-Macrophage (CAR-M) therapy; and Suzhou GenAssist Therapeutics Co., Ltd. to develop circVec-enhanced AAV vectors engineered for in vivo cell therapy and low dose systemic gene therapy. The company was formerly known as Targovax ASA and changed its name to Circio Holding ASA in May 2023. Circio Holding ASA was incorporated in 2010 and is based in Oslo, Norway.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Erik Digman Wiklund
  • Employees10
  • HeadquartersTordenskiolds gate 2, Oslo, Norway, 0160, Norway
  • Websitehttps://www.circio.com

Leadership

  • Dr. Erik Digman WiklundChief Executive Officer
  • Dr. Lubor Gaal Ph.D.Chief Financial Officer · b. 1969
  • Mr. Ola MelinChief Operating Officer
  • Dr. Thomas Birkballe HansenChief Technology Officer
  • Dr. Victor Levitsky M.D., Ph.D.Chief Scientific Officer
  • Mr. Jon Amund Eriksen M.Sc.Special Advisor
  • Prof. Gustav Gaudernack Ph.D.Chief Scientific Adviser
  • Dr. Peter Skorpil Ph.D.Vice President of Business Development

Financials

Income Statement

Currency: NOK2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue624.00K010.00M123.00K00
Growth (%)--100.00%--98.77%-100.00%-
Operating Income-103.90M-95.60M-493.59M-99.97M-42.49M-41.05M
Operating Margin-16650.80%--4934.92%-81272.36%--
EBITDA---97.66M-107.61M57.56M-45.71M
EBITDA Margin---976.41%-87488.62%--
Net Income-108.13M-97.97M-432.90M-112.94M57.52M-45.91M
Net Income Margin-17327.88%--4328.11%-91821.95%--
R&D-37.44M47.23M49.89M11.69M11.59M
R&D as % of Total Revenue--472.19%40560.98%--
Interest Expense-2.04M4.99M3.56M20.00K169.00K
Interest Expense % of Total Revenue--49.93%2891.87%--

Balance Sheet

Currency: NOK2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets520.74M565.27M100.41M25.71M21.83M10.76M
Total Liabilities148.15M147.54M97.85M124.25M34.34M23.25M
Total Equity372.59M417.73M2.57M-98.54M-12.51M-12.49M
Cash-178.18M62.97M21.90M18.21M6.04M
Net Debt---88.53M-2.32M

Cash Flow

Currency: NOK2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-110.79M-85.40M-108.84M-89.20M-40.53M-45.82M
Investing Cash Flow-70.00K0-4.96M2.95M-189.00K-
Financing Cash Flow163.53M145.61M-4.33M41.93M36.63M-
Capital Expenditure70.00K04.96M193.00K189.00K0
Free Cash Flow--85.40M-113.80M-89.39M-40.72M-45.82M
FCF to OCF-100.00%104.56%100.22%100.47%100.00%

Earnings

Report DateJun 30, 2014Sep 30, 2014Dec 31, 2014Mar 31, 2015Jun 30, 2015Sep 30, 2015Dec 31, 2015Mar 31, 2016Aug 31, 2016Nov 17, 2016Feb 16, 2017Apr 25, 2017Aug 24, 2017Nov 2, 2017Feb 15, 2018May 3, 2018Aug 23, 2018Nov 1, 2018Feb 14, 2019May 9, 2019Aug 22, 2019Nov 7, 2019Mar 11, 2020May 7, 2020Aug 20, 2020Nov 5, 2020Feb 18, 2021May 6, 2021Aug 18, 2021Nov 4, 2021Feb 17, 2022May 12, 2022Aug 18, 2022Nov 3, 2022Feb 15, 2023May 11, 2023Nov 9, 2023Jan 24, 2024Apr 26, 2024Apr 14, 2027
EPS Estimate----------22.32--24.74--19.50--25.20--21.00-21.30-23.40-22.80-19.80--18.00-13.65--8.55-9.30-9.60-8.85-8.40-4.50-3.90-4.50-4.80-0.20-6.02-6.02-6.02-
EPS Actual-5.69-8.12-16.89-13.52-25.55-20.31-29.19-22.10-23.85-18.30-14.52-19.50-15.66-17.70-12.02-19.80-13.71-19.80-23.10-23.10-21.60-12.30-10.96-10.80-13.20-5.96-9.30-7.80-9.00-8.10-8.40-4.80-4.50-3.30-3.60-0.28-8.40-8.40-8.40-
Surprise---------18.01%-21.18%-9.23%-21.43%-5.71%-8.45%1.28%5.26%37.88%-40.00%3.30%--8.77%16.13%6.25%8.47%0.00%-6.67%-15.38%26.67%25.00%-40.00%-39.53%-39.53%-39.53%-
Timing---------Pre-market-Pre-market-Pre-market-Pre-market-Pre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-market-Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-market

Key Statistics & Ratios

Market Cap3.11B
Enterprise Value2.53B
Trailing P/E0.00
Forward P/E0.00
Price / Sales70.91
Price / Book5.92
EPS-0.37
Book Value1.89
Revenue (TTM)123.00K
Gross Profit (TTM)123.00K
EBITDA-63.02M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-25.55%
Return on Assets-14.11%
Shares Outstanding290.97M
Shares Float218.85M
Beta-1.11
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Oct 4, 20231:30